The incidence of breast cancer is much higher in these countries, and with superior efficacy of PARP inhibitors as compared to other available cancer treatment options, the PARP inhibitors market is expected to gain significant revenue over the forecast period.
The global PARP inhibitors market is estimated to be valued at US$ 8.4 Bn by 2026, expanding at a significant CAGR from 2022 to 2026.
Rising burden of various types of cancers such as ovarian, breast, prostate, and pancreatic cancer is anticipated to generate significant demand for PARP inhibitors. According to the Global Cancer Observatory (GLOBOCAN), countries such as China, the U.S., India, and Japan, collectively diagnose over 120,000 new cases of ovarian cancer each year.
Request a report sample to gain comprehensive insights at
|PARP Inhibitors Market Estimated Size in 2022||US$ 5.51 Bn|
|PARP Inhibitors Market Projected Size in 2026||US$ 8.43 Bn|
|PARP Inhibitors Market Historical CAGR (2014-2021)||90.4%|
|PARP Inhibitors Market Value-based CAGR (2022-2026)||11.2%|
Key Takeaways of PARP Inhibitors Market Study
- Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2021, and will continue to do so during the forecast period.
- PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.
- With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.
For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-3197
Strategic Acquisitions & Collaborations by Key Players to Widen Regional Presence
All marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings.
For example, in January 2022, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).
More Valuable Insights on PARP Inhibitors Market
Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2015 to 2026. The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The study provide compelling insights on PARP inhibitors market on basis of drug (Olaparib, Niraparib, Rucaparib, and Talazoparib), indication (ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer), and distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies), across seven major regions.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-3197
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain
SGLT2 Inhibitors Treatment Market – SGLT2 Inhibitors Treatment market is looking forward to grow at a higher rate in the forecast period of 2021-2031. SGLT2 Inhibitors help in reabsorption of glucose from the kidney leading to low blood glucose level.
Bromodomain and Extraterminal Domain (BET) Inhibitors Market – Bromodomain and extraterminal domain (BET) Inhibitors are small molecule inhibitors which have proliferating properties. The bromodomain and extraterminal domain (BET) inhibitors have immunosuppressive and anti-cancer properties.
NF-KB Inhibitors Market – NF-KB inhibitors are the drugs that are used in controlling the activity of NF-KB. NF-KB is a transcription factor, found to be involved in the regulation of around 500 genes that are responsible for several functions such as cell proliferation, metastasis, survival invasion, inflammation, and angiogenesis.
Interleukin-6 (IL-6) Inhibitors Market – Interleukin-6 (IL-6) inhibitors are the inhibitors of cytokine Interleukin-6 (IL-6) to curb the diseases and symptoms induced by Interleukin-6 such as fever, inflammations, and autoimmune diseases including arthritis, asthma and cancer.
Janus Kinase (JAK) Inhibitors Market – Janus Kinase (JAK) inhibitors are small molecules that can be administrated orally. In addition, they are trouble free in reaching the inside of cells and inhibit intracellular signaling molecules directly.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: firstname.lastname@example.org
For Media Enquiries: email@example.com